Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
Top

09-29-2020 | EASD 2020 | Conference coverage | Article

EMPEROR-Reduced: Time for a change in the HF guidelines?

print
PRINT
insite
SEARCH

Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Related content

09-01-2020 | Empagliflozin | News

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

09-02-2019 | Heart failure | Highlight | News

Dapagliflozin ‘offers a new approach’ for treating heart failure

09-19-2019 | Heart failure | Video | Article

Expert commentary: DAPA-HF and DEFINE-HF trial results

09-25-2020 | EASD 2020 | Conference coverage | Article

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes
Image Credits